26 Apr 2024 by admin in UncategorizedComments Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis
08 Apr 2024 by admin in UncategorizedComments Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
29 Mar 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
26 Mar 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
06 Mar 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Patricia Allen to its Board of Directors
07 Feb 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
29 Jan 2024 by admin in UncategorizedComments Oricell Announces FDA Clearance of IND Application for OriCAR- 017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company’s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma
25 Jan 2024 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
18 Jan 2024 by admin in UncategorizedComments NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
15 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
